Advanced Melanoma Survival Improves Significantly When Immunotherapy is Given Before Targeted Therapy
Lombardi Comprehensive Cancer Center at Georgetown UniversityA clinical trial led by clinicians at Georgetown Lombardi Comprehensive Cancer Center showed a remarkable 20 percent advantage in the two-year overall survival rate for people with advanced melanoma who first received immunotherapy (72 percent survival rate) versus those who initially got targeted therapies (52 percent survival rate). Progression-free survival, where the cancer is stable or improving, was also trending in favor of those who started on immunotherapy.